Marissa Pettit
Acute Care · Albuquerque, NMNPI 1831528090
Payments from drug & device makers
What this record shows
This record is dominated by other: $2,115 of the $3,479 with a category attached, or 60.8%. Novartis accounts for 64.5% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $1,452, 8.7 times the $167 reported in 2021. Among acute care clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $40.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- AstraZeneca$413
- Gilead$168
- Daiichi Sankyo Inc.$121
- Ipsen Biopharmaceuticals, Inc$113
- Merck$85
- plus $335 from 9 others
What the payments were for
- Food & beverage$1,36439%
- Other$2,11561%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 31 | $2,244 |
| AstraZeneca | 20 | $413 |
| Gilead | 8 | $168 |
| Daiichi Sankyo Inc. | 6 | $121 |
| Ipsen Biopharmaceuticals, Inc | 1 | $113 |
| Merck | 4 | $85 |
| Lilly USA, LLC | 5 | $82 |
| Astellas Pharma US Inc | 2 | $54 |
| Pfizer | 1 | $37 |
| Beigene USA, Inc. | 2 | $35 |
| Foundation Medicine, Inc. | 1 | $33 |
| Pharmaand GmbH | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Mylan Institutional Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOMATULINE DEPOT$113
How this compares
$3,479 in reported general payments places this provider in the 90th percentile of 132 acute care providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 62 | $1,051 |
| Tamoxifen Citrate | 12 | $506 |
| Letrozole | 18 | $321 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $209 |
| Escitalopram Oxalate | 12 | $143 |
| Gabapentin | 16 | $111 |
| Levothyroxine Sodium | 13 | $19 |
Paid to pharmacies, not to this prescriber.
Other acute care in Albuquerque
- Taryn DenezpiAlbuquerque$11K
- Catherine MahoneyAlbuquerque$10K
- Samantha MatteucciAlbuquerque$8K
- Isabel TorresAlbuquerque$5K
- Kalina CordovaAlbuquerque$4K
- Christine ObergAlbuquerque$3K
- Robyn MitchellAlbuquerque$2K
- Jessica KnightAlbuquerque$2K
- Audrey ClarkAlbuquerque$2K
- John MackenzieAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.